- Home
- CGON vs TRIP Comparison
CGON vs TRIP Comparison
Compare CGON & TRIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGON
- TRIP
- Stock Information
- Founded
- CGON 2010
- TRIP 2000
- Country
- CGON United States
- TRIP United States
- Employees
- CGON N/A
- TRIP N/A
- Industry
- CGON
- TRIP Computer Software: Programming Data Processing
- Sector
- CGON
- TRIP Technology
- Exchange
- CGON NYSE
- TRIP Nasdaq
- Market Cap
- CGON 2.0B
- TRIP 2.1B
- IPO Year
- CGON 2024
- TRIP 2011
- Fundamental
- Price
- CGON $26.91
- TRIP $17.56
- Analyst Decision
- CGON Strong Buy
- TRIP Hold
- Analyst Count
- CGON 11
- TRIP 14
- Target Price
- CGON $63.30
- TRIP $17.73
- AVG Volume (30 Days)
- CGON 979.0K
- TRIP 4.1M
- Earning Date
- CGON 08-07-2025
- TRIP 08-07-2025
- Dividend Yield
- CGON N/A
- TRIP N/A
- EPS Growth
- CGON N/A
- TRIP 115.16
- EPS
- CGON N/A
- TRIP 0.37
- Revenue
- CGON $662,000.00
- TRIP $1,838,000,000.00
- Revenue This Year
- CGON N/A
- TRIP $7.52
- Revenue Next Year
- CGON $21,843.29
- TRIP $7.50
- P/E Ratio
- CGON N/A
- TRIP $46.72
- Revenue Growth
- CGON 224.51
- TRIP 1.44
- 52 Week Low
- CGON $14.80
- TRIP $10.43
- 52 Week High
- CGON $40.47
- TRIP $18.66
- Technical
- Relative Strength Index (RSI)
- CGON 54.12
- TRIP 58.92
- Support Level
- CGON $25.14
- TRIP $17.51
- Resistance Level
- CGON $27.09
- TRIP $18.20
- Average True Range (ATR)
- CGON 1.50
- TRIP 0.56
- MACD
- CGON -0.04
- TRIP -0.12
- Stochastic Oscillator
- CGON 53.56
- TRIP 32.37
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).